Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic.

Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for ...

The gene editing company CRISPR Therapeutics surprisingly struck a deal with China-based biotech Sirius Therapeutics to ...

Senate Democrats grilled Kennedy on Tuesday over gaps in his budget and funding cuts that have halted or eliminated key ...

SV Health closes $269M dementia fund, Schrödinger cuts 60 jobs, Beckley Psytech's BPL-003 shows promise in depression, and ...

Under the program that was first announced by President Trump last week, the US would target prices based on benchmarks from ...

Calibrate names Rob Rebak as new CEO, replacing Rob MacNaughton, amid executive changes. CFO and Chief Clinical Officer also ...

FDA chief Marty Makary and new CBER Director Vinay Prasad said that future Covid-19 vaccine approvals will focus on adults ...

Biotech execs express concerns over FDA changes, NIH cuts, and Trump's tariffs. Industry confidence low amid poor funding ...

Pfizer is dishing out $1.25 billion upfront and up to $4.8 billion in milestone payments to Shenyang-based 3SBio for the ...

A longevity startup called Retro Biosciences is working on personalized blood disorder therapies thanks to a partnership with ...

Intellia's CRISPR therapy nexiguran ziclumeran maintained reductions in the levels of a misfolded protein in the nerves of ...